8-K: scPharmaceuticals Reports Strong Q4 and Full Year 2024 Results, Fueled by FUROSCIX Growth and Expanded Label

scPharmaceuticals announces positive financial results for Q4 and full year 2024, driven by significant revenue growth of FUROSCIX and FDA approval for chronic kidney disease indication.

Summary

• scPharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Net FUROSCIX revenue for Q4 2024 was $12.2 million, and full year revenue was $36.3 million.
• This represents a 99% increase in Q4 revenue and a 167% increase in full year revenue compared to 2023.
• Approximately 13,300 FUROSCIX doses were filled in Q4 2024, a 23% increase from Q3 2024.
• For the full year 2024, approximately 41,000 FUROSCIX doses were filled.
• The gross-to-net (GTN) discount was 19% for Q4 2024 and 16% for the full year.
• The company had approximately 3,800 unique prescribers from launch through year end 2024, up approximately 23% from the end of the third quarter.
• scPharmaceuticals ended 2024 with $75.7 million in cash and cash equivalents.
• The FDA approved the expanded FUROSCIX label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease on March 6, 2025.
• The company anticipates formally launching the new indication in April 2025.
• The company is targeting a supplemental New Drug Application (sNDA) submission for the SCP-111 Autoinjector 80mg/1mL FUROSCIX program mid-year.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, FDA approval, and advancement of key programs. While the net loss is a concern, the company's growth trajectory and strategic initiatives suggest a promising future.

Positives

• Significant revenue growth for FUROSCIX in both Q4 and full year 2024.
• FDA approval for expanded FUROSCIX indication to include chronic kidney disease.
• Increase in FUROSCIX doses filled, indicating growing demand.
• Continued expansion into Integrated Delivery Networks (IDNs), with 123% growth from the third quarter of 2024.
• Advancement of the SCP-111 Autoinjector program with a targeted sNDA submission mid-year.
• Strong cash position at the end of 2024.

Negatives

• The company reported a net loss of $18.8 million for Q4 2024 and $85.1 million for the full year 2024.
• Selling, general and administrative (SG&A) expenses increased significantly for both Q4 and full year 2024.
• Cost of product revenues increased due to higher demand and related manufacturing costs.

Risks

• The company's dependence on the commercial success of FUROSCIX.
• Risks related to obtaining regulatory approval for product candidates.
• The company has a history of operating losses and expects to incur significant and increasing losses for the foreseeable future.
• The company may need additional funding and may be unable to raise capital when needed.
• Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome.

Future Outlook

scPharmaceuticals is focused on expanding the FUROSCIX franchise, including launching the new CKD indication and advancing the autoinjector program, and anticipates continued growth driven by these initiatives and the Medicare Part D redesign.

Management Comments

• We were pleased to receive approval of FUROSCIX in CKD from the FDA, which we believe is a critical market opportunity for scPharmaceuticals and a core component of the long-term franchise expansion plans for FUROSCIX.
• The nephrologists in our preliminary call points understand where FUROSCIX fits into the treatment paradigm, and the benefits it can bring to these patients when they experience fluid overload.
• As we focus on 2025, we remain encouraged by the significant tailwinds, including scPharmaceuticals expanded field sales force, the indication expansion into the CKD market, and the full year impact of the Medicare Part D redesign.

Industry Context

The announcement reflects a growing trend in pharmaceutical companies focusing on patient-centric innovations and expanding treatment options for chronic conditions like heart failure and kidney disease. The focus on home-based treatment solutions aligns with the broader industry shift towards value-based care and reducing hospital readmissions.

Comparison to Industry Standards

• Compared to companies like SteadyMed (acquired by United Therapeutics) which also focused on subcutaneous drug delivery, scPharmaceuticals has achieved significant commercial traction with FUROSCIX.
• The 167% revenue growth year-over-year is substantial, exceeding the average growth rate for specialty pharmaceutical companies in the cardiorenal space.
• The potential 70% cost reduction with the autoinjector, if approved, could provide a significant competitive advantage compared to traditional IV diuretic administration.

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth and potential for future profitability.
• Patients: Improved treatment options and potential for reduced healthcare costs.
• Employees: Job security and potential for career advancement due to company growth.
• Healthcare providers: New treatment options for managing fluid overload in patients with heart failure and kidney disease.

Next Steps

• Formally launch the new FUROSCIX indication for chronic kidney disease in April 2025.
• Submit a supplemental New Drug Application (sNDA) for the SCP-111 Autoinjector 80mg/1mL FUROSCIX program mid-year.
• Continue commercial expansion efforts, including leveraging the expanded field sales force and the Medicare Part D redesign.

Key Dates

Keywords

FUROSCIX, scPharmaceuticals, revenue, chronic kidney disease, CKD, financial results, autoinjector, FDA approval, edema, cardiorenal